Journal News

JBC: A sugar-attaching enzyme defines colon cancer

Sasha Mushegian
June 01, 2018

Researchers have identified an enzyme that is absent in healthy colon tissue but abundant in colon cancer cells, according to a paper published in the Journal of Biological Chemistry.

The enzyme GalNAc-T6 is upregulated selectively in colon adenocarcinomas, and its expression is associated with a cancerlike growth pattern.courtesy of Kirstine Lavrsen/University of Copenhagen

The enzyme appears to drive the conversion of normal colon tissue into cancer by attaching sugar molecules, or glycans, to certain proteins in the cell. Understanding the role that sugar-modified proteins play in healthy and cancerous cells is an emerging area of cancer biology that may lead to new therapies.

Hans Wandall’s team at the University of Copenhagen studied 20 enzymes that initiate the first step in a particular kind of glycan modification, called GalNAc-type O-glycosylation, found on diverse proteins. These enzymes, called GalNAc transferases, or GalNAc-Ts, are found in different amounts in different tissues, but their functions are poorly understood.

Wandall’s team, led by then-graduate student Kirstine Lavrsen, found that one of the GalNAc-Ts, called GalNAc-T6, was absent in healthy colon tissue but abundant in colon cancer cells. The team used CRISPR/Cas engineering of a colon cancer cell line with and without GalNAc-T6 to understand to which proteins the enzyme helped attach sugars and what effect this had on the cells.

“When we look at the 3D growth of a cancer cell line that has GalNAc-T6, it can form tubular structures with formation of something that looks like colon cancer tissue,” Wandall said. “When we take out GalNAc-T6, then suddenly the tissue formation changes to look more like the crypt structures that you would find in a healthy colon.”

Using mass spectrometry, the team categorized the proteins that GalNAc-T6 acted on in these cells.

“Our data suggest (that) this specific enzyme seems to affect a subset of proteins that could be involved in cell-cell adhesion,” Wandall said. In other words, the glycan modifications changed the patterns in which cells stuck together, leading the cells to develop as something that looked more like a tumor than a healthy tissue.

The next step is to understand precisely why adding sugars to the specific protein sites modified by GalNAc-T6 leads colon cells to develop abnormally. Glycan modifications can affect protein function in myriad ways. For example, they can make proteins that usually are cleaved into two unable to be cleaved, or prevent two proteins from binding to each other.

Wandall hopes that understanding glycosylation in cancer cells will lead to better early diagnostic tools, drugs or immunotherapies.

“Glycans add an additional context layer that could help us create more specific interventions,” he said.

“Glycans look so different in cancer compared to normal tissue, and it’s a really understudied field,” Lavrsen said. “There are a lot of things to be discovered.”

Sasha Mushegian

Sasha Mushegian is a postdoctoral fellow at Georgetown University. Follow her on Twitter.

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in Science

Science highlights or most popular articles

Branon works to break barriers in science and higher education
ASBMB Annual Meeting

Branon works to break barriers in science and higher education

March 03, 2021

Tess Branon will speak during the Molecular & Cellular Proteomics early career researcher session on proximity-dependent biotinylation at the 2021 ASBMB Annual Meeting.

Brain Injury Awareness Month 2021
Health Observance

Brain Injury Awareness Month 2021

March 01, 2021

In the U.S., about 2.8 million people sustain a traumatic brain injury annually. Learn about recent research on TBI-related dementia, dysfunctional mitochondria and other work powering the march toward better therapies.

The evolution of proteins from mysteries to medicines
Essay

The evolution of proteins from mysteries to medicines

February 27, 2021

An essay in observance of National Protein Day.

'Every experiment and every breakthrough matters'
Health Observance

'Every experiment and every breakthrough matters'

February 26, 2021

An interview with NYMC dean Marina K. Holz, who studies a rare disease that affects women of childbearing age.

Progeria: From the unknown to the first FDA-approved treatment
Health Observance

Progeria: From the unknown to the first FDA-approved treatment

February 25, 2021

Hutchinson–Gilford progeria syndrome is a rare, fatal genetic disease that causes premature aging.

Raising awareness and funding for Pompe disease
Health Observance

Raising awareness and funding for Pompe disease

February 25, 2021

Father-turned-advocate has founded multiple organizations to support families and search for better therapies for people with rare lysosomal storage disorder.